Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

Even if they’re not acquired, these small companies are developing promising obesity and diabetes treatments.

Previous post J.B. Hunt sees lower volumes, weaker demand; stock drops 6%
Next post Inflation in New Zealand eases, but rate cuts unlikely in near term